How a rod the size of a matchstick can change the world

LANETA DORFLINGER, PhD
Director, Contraceptive Technology Innovation
Contraceptive Effectiveness

Over 90% of unintended pregnancies occur among women using no method or less effective methods\(^1\)

<table>
<thead>
<tr>
<th>More effective</th>
<th>Less than 1 pregnancy per 100 women in 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUD</td>
<td>Female sterilization</td>
</tr>
<tr>
<td>2007</td>
<td>Injectables</td>
</tr>
<tr>
<td>Injectables</td>
<td>LAM</td>
</tr>
<tr>
<td>Male condoms</td>
<td>Diaphragm</td>
</tr>
<tr>
<td>Less effective</td>
<td>About 30 pregnancies per 100 women in 1 year</td>
</tr>
<tr>
<td>Withdrawal</td>
<td>Spermicides</td>
</tr>
</tbody>
</table>

Do not require regular action by user
Continuation rates much higher
Cost-effective

1 Source: www.guttmacher.org
Impact of Effectiveness
Implants vs. Shorter-acting Methods

If 20% of OC or injectable users in Africa switched to implants -- over 5 years, it would avert:

- 1.8 million unplanned pregnancies
- 576,000 abortions
- 10,000 maternal deaths

The impact would be more dramatic adding new users!

Hubacher, Mavranezouli, and McGinn, *Contraception* 2008
Low-cost Alternative Identified in 2007
Sino-implant (II)
Innovative Public-Private Sector Partnership
Sino-implant (II) Initiative (2007-present)

Global Coordinator
FHI 360

Manufacturer: Shanghai Dahua Pharmaceuticals Co., Ltd.

Funding from the Bill & Melinda Gates Foundation
FHI 360’s Global Coordination Role

FHI 360 provides technical assistance to support Sino-implant (II) introduction in resource-constrained settings.

- Support for national registrations
- Product quality testing & Post-marketing studies
- Technical support for country introduction
- Support for WHO Prequalification
Sino-implant (II) Registration Status
Aug 2015

Registered (n=26)
- Bolivia‡
- Burkina Faso†
- Cambodia†
- Chile
- China
- Dem Rep. of Congo†
- Ethiopia**
- Fiji†
- Ghana†
- Guatemala†
- Indonesia
- Jamaica
- Kenya‡
- Madagascar‡
- Mali‡
- Mongolia†
- Mozambique‡
- Nigeria‡
- Pakistan†
- Senegal†
- Sierra Leone‡
- Uganda‡
- Vietnam†
- Zambia‡
- Zanzibar‡

Under review in over 10 additional countries
- Distributed by Marie Stopes International (MSI);
- Distributed by Pharm Access Africa Ltd. (PAAL)
- Distributed by DKT International
- Distributed by APROFAM
1 Million Sino-implant (II) Distributed 2009-2013

According to the MSI Impact Calculator:
• 1.4 million unintended pregnancies averted
• Over 3000 maternal deaths averted
• Over 175,000 abortions averted

In addition, units translate into
• $10.5 million units in commodity cost savings*

Savings mean that an additional 1.3 million units of Sino-implant (II) could have been purchased

*Impact is estimated based on distribution of 1,000,100 units. Savings are based on a price of US$8 per unit for Sino-implant (II), assuming the alternative would have been to purchase Jadelle. The average price for Jadelle was US$24 in 2009, US$22 in 2010, US$19 in 2011, US$18 in 2012, and $8.50 in 2013 according to information from the RHSC (www.rhsupplies.org).
Contraceptive Implant Prices 2009-2013: Changes Since Global Introduction of Sino-implant (II)

2009: Sino-implant (II) registered in Kenya under trade name Zarin

2011-2012: Merck/MSD reduces price of Implanon to $18/unit, with retro-active reduction to $16.50 when volume thresholds reached in Dec 2012

2011-2012: Bayer HealthCare reduces price of Jadelle to $19/unit and then subsequently to $18/unit

2012-2013: Bayer HealthCare and Merck/MSD lower the prices of Jadelle and Implanon to US$8.50 per unit as part of volume guarantees

Prices established through volume guarantees last through 2018
Implants procured globally*

Important role of Sino-implant (II)

* Source: RH Interchange
Thank you...